Overview

A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this Phase II trial is to compare the efficacy and safety of 6 months of treatment with thymalfasin plus trans arterial chemoembolization (TACE) with TACE alone in adult patients with non-surgical hepatocellular carcinoma (HCC).
Phase:
Phase 2
Details
Lead Sponsor:
SciClone Pharmaceuticals
Treatments:
Thymalfasin